Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke

C Zerna; G Thomalla; BCV Campbell; JH Rha; MD Hill

Journal article

Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke

C Zerna, G Thomalla, BCV Campbell, JH Rha, MD Hill

Lancet | Published : 2018

DOI: 10.1016/S0140-6736(18)31874-9

Abstract

Even though stroke presents as a variety of clinical syndromes, neuroimaging is the most important biomarker to help differentiate between stroke subtypes and assess treatment eligibility. Therapeutic advances have led to intravenous thrombolysis with tissue-type plasminogen activator and endovascular treatment for proximal vessel occlusion in the anterior cerebral circulation being standard care for acute ischaemic stroke. Providing access to this care has implications for existing systems of care for stroke and their organisation and has reintroduced the possibility of adjuvant and neuroprotective treatment strategies in acute ischaemic stroke. The use of neuroimaging for patient selection..

View full abstract

University of Melbourne Researchers

Bruce Campbell Author

Grants

Funding Acknowledgements

BCVC reports grants from the Australian National Health and Medical Research Council, the Royal Australasian College of Physicians, the Royal Melbourne Hospital Foundation, National Heart Foundation, National Stroke Foundation of Australia, and Covidien (Medtronic), during this study. MDH reports personal fees from Merck, non-financial support from Hoffmann-La Roche Canada Ltd, grants from Covidien (Medtronic), Boehringer Ingelheim, Stryker Inc, and Medtronic LLC, outside the submitted work. MDH has a patent Systems and Methods for Assisting in Decision-Making and Triaging for Acute Stroke Patients pending to US Patent Office number 62/086,077 and owns stock in Calgary Scientific Incorporated, a company that focuses on medical imaging software, is a director of the Canadian Federation of Neurological Sciences, a not-for-profit group, and has received grant support from Alberta Innovates Health Solutions, Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, and the National Institute of Neurological Disorders and Stroke. All other authors declare no competing interests.